Does Insurance Cover Testosterone Therapy? What to Know Before You Start

Testosterone therapy coverage is generally available through most major insurance plans, including Medicare, but it depends heavily on meeting specific diagnostic criteria first, not simply requesting treatment based on symptoms alone. Understanding what plans actually require before approving coverage can prevent a frustrating and avoidable denial.

The diagnostic criteria that drive coverage decisions

Most insurance plans, following the same clinical guidelines used to diagnose low testosterone in the first place, require a documented total testosterone level below approximately 300 ng/dL, confirmed on at least two separate morning blood draws, along with documented symptoms consistent with low testosterone (low libido, fatigue, reduced muscle mass, or similar). Both elements, the lab criteria and the symptoms, are generally required together, since guidelines specify that neither alone is sufficient for a diagnosis of hypogonadism warranting treatment.

A single low reading, without the confirmatory second draw, is one of the most common reasons an initial coverage request faces pushback, even when the underlying clinical picture may genuinely warrant treatment. Following the correct testing protocol, two morning draws rather than one, from the outset avoids this entirely.

Why the specific formulation matters

Not all testosterone therapy formulations are covered equally. Generic injectable testosterone is generally the most consistently and readily covered option across plans. Newer formulations, certain topical gels, or pellet-based delivery systems, sometimes face more restrictive prior authorization requirements or higher cost-sharing, even when clinically appropriate, simply because of how formularies are structured. If cost or coverage is a significant concern, this is worth discussing directly with your prescribing clinician, since a formulation switch alone can sometimes resolve a coverage barrier.

What happens with a borderline result

A testosterone level that is borderline, not clearly below the diagnostic threshold, but low enough to raise a genuine clinical question, is more likely to face coverage challenges, since it does not clearly meet the documented criteria plans use for approval. This is part of why accurate, correctly-timed testing, morning draws specifically, since testosterone is highest in the morning, matters from the start rather than testing at a time of day that might understate your actual level.

What to do if coverage is denied

If an initial request is denied, reviewing the specific reason for denial, often a documentation gap rather than a fundamental coverage exclusion, and working with your clinician's office to submit the additional needed documentation (a confirmatory second draw, more detailed symptom documentation) can frequently reverse the decision on appeal.

Getting this right from the start

Following the correct diagnostic protocol, two confirmed morning draws plus documented symptoms, from the beginning gives you the strongest position for coverage approval and avoids an unnecessary initial denial and appeal process. Most major insurance plans, including Medicare, cover testosterone therapy when this documentation is in place.